表紙
市場調査レポート

大手バイオテクノロジー企業50社の事業提携および企業合併・買収(M&A)の傾向

Top 50 Big Biotech Partnering and M&A Deal Trends

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 315590
出版日 ページ情報 英文 565 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
大手バイオテクノロジー企業50社の事業提携および企業合併・買収(M&A)の傾向 Top 50 Big Biotech Partnering and M&A Deal Trends
出版日: 2015年04月13日 ページ情報: 英文 565 Pages
概要

当レポートでは、世界の最大手バイオテクノロジー企業50社における事業提携および企業合併・買収(M&A)の動向について分析し、過去4年間の資本取引件数やその内容・目的・取引額、開発段階・治療領域別などの詳細動向、目的の達成状況、提携・取引機会の形成方法、主要企業のプロファイル(過去の提携動向、現在までの製品開発状況、得意分野、経営状況など)といった情報をお届けいたします。

エグゼクティブ・サマリー

第1章 イントロダクション

第2章 大手バイオテクノロジー企業50の資本取引活動

  • イントロダクション
  • 過去数年間の事業提携の傾向
  • 事業提携の傾向:取引の種類別
  • 事業提携の傾向:開発段階別
  • 事業提携の傾向:技術の種類別
  • 事業提携の傾向:治療領域別
  • 過去数年間の企業合併・買収(M&A)の傾向

第3章 大手バイオテクノロジー企業の資本取引額

  • イントロダクション
  • 事業提携の場合
  • M&Aの場合

第4章 大手バイオテクノロジー企業の取引提案機会

  • 取引機会の提案方法
  • 取引提案の定番の方法
  • eメールの送付
  • 商談会での直接提案
  • オンラインの提案フォーム

第5章 大手バイオテクノロジー企業にとっての今後の提携機会

  • 今後の提携機会

第6章 大手バイオテクノロジー企業のプロファイル

  • イントロダクション
  • 分野の定義
  • 企業プロファイル
    • Acorda Therapeutics
    • Actavis
    • Actelion
    • Alexion Pharmaceuticals
    • Alkermes
    • Allergan
    • Amgen
    • Bavarian Nordic
    • Biocon
    • Biogen Idec
    • BioMarin Pharmaceuticals
    • Celgene
    • CSL
    • Cubist
    • Dendreon
    • Emergent BioSolutions
    • Endo International
    • Galapagos
    • Genmab
    • Gilead Sciences
    • Grifols
    • Ipsen
    • Isis Pharmaceuticals
    • Jazz Pharmaceuticals
    • LFB Group
    • Medivation
    • Merck KGaA
    • Morphosys
    • Nektar Therapeutics
    • Novo Nordisk
    • NPS Pharmaceuticals
    • PDL BioPharma
    • Pharmacyclics
    • Questcor Pharmaceuticals
    • Regeneron Pharmaceuticals
    • Roche
    • Salix Pharmaceuticals
    • SciClone Pharmaceuticals
    • Seattle Genetics
    • Shire
    • Spectrum Pharmaceuticals
    • Sun Pharmaceutical
    • Swedish Orphan Biovitrum
    • Teva
    • The Medicines Company
    • UCB
    • United Therapeutics
    • Valeant
    • Vertex Pharmaceuticals
    • Zeltia

第7章 情報源

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP1011

Executive Summary

The ‘Top 50 Big Biotech Partnering and M&A Deal Trends 2010-2015’ report provides the most comprehensive and in-depth insight into the dealmaking activity of the world's leading fifty biotech companies.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives. Over 300 charts allow quick understanding of each big biotech companies dealmaking trends over the last four years.

The initial chapters of this report provide an orientation of big biotech's dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading big biotech companies based on 2012 pharmaceutical revenues and dealmaking activity since 2010.

Chapter 3 reviews the top partnering and M&A deals of 2010-2015 according to reported deal size.

Chapter 4 provides a summary on best practice on how to submit an opportunity to big biotech, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 5 lists forthcoming partnering events where valuable face to face meetings with big biotech provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in chapter 6. In-depth profiles of every big biotech company provide everything required to assess the suitability of a company as a prospective partner. Each profile includes a company overview, partnering activity according to deal type, phase of development, therapy area and technology type.

Each company profile provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of a prospective partner's negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This data driven report contains over 2,000 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In addition, contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In summary, the report provides the reader with the tools necessary to make successful contact with the right big biotech partners effectively and efficiently.

Key benefits

‘Top 50 Big Biotech Partnering and M&A deal Trends’ provides the user with the following key benefits:

  • Detailed partnering activity profiles for each of the top 50 big biotech companies
  • Over 300 charts showing a company's dealmaking activity since 2010, allowing quick identification potential partners
  • Partnering therapy focus revealed
  • Partnering activity since 2010 - number of deals per year
  • Partnering activity for 2010-2015 o Full listing of partnering deals
    • Activity by deal type
    • Activity by industry sector
    • Activity by phase of development
    • Activity by technology type
    • Activity by therapeutic area
  • Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available
  • Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
  • Understand the key deal terms the company has agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Top 50 Big Biotech Partnering and M&A deal Trends’ is intended to provide the reader with an in-depth understanding of the partnering activities of the leading fifty big biotech companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company's partnering.

‘Top 50 Big Biotech Partnering and M&A deal Trends’ includes:

  • Detailed company profiles for each of the top 50 big biotech companies, including: o Partnering interests and indications
    • Partnering activity since 2010
    • Partner companies since 2010
    • Partnering activity since 2010 by:
      • Partner company
      • Deal type
      • Industry sector
      • Stage of development
      • Technology type
      • Therapy area
  • Over 300 charts showing the dealmaking activity of each company since 2010
  • The tools to enable effective and efficient preparation for partnering negotiation with big biotech
  • 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available
  • The leading M&A and partnering deals by value 2010-2015

The ‘Top 50 Big Biotech Partnering and M&A deal Trends’ report also provides comprehensive access to available contract documents for each of the fifty big biotech companies. Analyzing actual company agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subscontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Big biotech top 50 dealmaking activity

  • 2.1. Introduction
  • 2.2. Big biotech partnering over the years
  • 2.3. Big biotech partnering by deal type
  • 2.4. Big biotech partnering by stage of development
  • 2.5. Big biotech partnering by technology type
  • 2.6. Big biotech partnering by therapy area
  • 2.7. Big biotech M&A over the years

Chapter 3 - Top big biotech deals by value

  • 3.1. Introduction
  • 3.2. Big biotech partnering
  • 3.3. Big biotech M&A

Chapter 4 - Submitting Opportunities to Big biotech

  • 4.1. How to submit an opportunity
  • 4.2. Opportunity submission template
  • 4.3. Sending emails
  • 4.4. Face to face at partnering events
  • 4.5. Online submission forms

Chapter 5 - Forthcoming big biotech partnering events

  • 5.1. Forthcoming events

Chapter 6 - Big Biotech Company Profiles

  • 6.1. Introduction
  • 6.2. Field definitions
  • 6.3. Company profiles
    • Acorda Therapeutics
    • Actavis
    • Actelion
    • Alexion Pharmaceuticals
    • Alkermes
    • Allergan
    • Amgen
    • Bavarian Nordic
    • Biocon
    • Biogen Idec
    • BioMarin Pharmaceuticals
    • Celgene
    • CSL
    • Cubist
    • Dendreon
    • Emergent BioSolutions
    • Endo
    • Galapagos
    • Genmab
    • Gilead Sciences
    • Grifols
    • Ipsen
    • Isis Pharmaceuticals
    • Jaxx Pharmaceuticals
    • LFB Group
    • Medivation
    • Merck KGaA
    • Morphosys
    • Nektar Therapuetics
    • Novo Nordisk
    • NPS Pharmaceuticals
    • PDL BioPharma
    • Pharmacyclics
    • Questcor Pharmaceuticals
    • Regeneron Pharmaceuticals
    • Roche
    • Salix Pharmaceuticals
    • SciClone Pharmaceuticals
    • Seattle Genetics
    • Shire
    • Spectrum Pharmaceuticals
    • Sun Pharmaceutical
    • Swedish Orphan Biovitrum
    • Teva
    • The Medicines Company
    • UCB
    • United Therapeutics
    • Valeant
    • Vertex Pharmaceuticals

Chapter 7 - Resources

Appendices

  • Appendix 1 - Deal type definitions
  • Appendix 2 - Example contract document
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering

Order Form - Upgrades to subscription access products

TABLE OF FIGURES

  • Figure 1: Big biotech partnering 2010-2015
  • Figure 2: Big biotech - top 50 partnering activity 2010 to 2015
  • Figure 3: Big biotech deal frequency - 2010 to 2015
  • Figure 4: Big biotech partnering by deal type 2010-2015
  • Figure 5: Big biotech partnering by stage of development 2010-2015
  • Figure 6: Big biotech partnering by technology type 2010-2015
  • Figure 7: Big biotech partnering by therapy area 2010-2015
  • Figure 8: Big biotech M&A 2010-2015
  • Figure 9: Big biotech - top 50 M&A activity 2010-2015
  • Figure 10: Big biotech M&A deal frequency 2010-2015
  • Figure 11: Leading partnering deals by value, 2010-2015
  • Figure 12: Leading M&A deals involving big biotech by value, 2010-2015
  • Figure 13: Typical partnering opportunity submission template
  • Figure 14: Company profile template and definitions used in report
  • Figure 15: Acorda Therapeutics dealmaking frequency 2010-2015
  • Figure 16: Acorda Therapeutics deals by type
  • Figure 17: Acorda Therapeutics deals by industry sector
  • Figure 18: Acorda Therapeutics deals by technology type
  • Figure 19: Acorda Therapeutics deals by stage of development
  • Figure 20: Partnering deals by therapy area
  • Figure 21: Actavis dealmaking frequency 2010-2015
  • Figure 22: Actavis deals by type
  • Figure 23: Actavis deals by industry sector
  • Figure 24: Actavis deals by technology type
  • Figure 25: Actavis deals by stage of development
  • Figure 26: Actavis deals by therapy area
  • Figure 27: Actelion dealmaking frequency 2010-2015
  • Figure 28: Actelion deals by type
  • Figure 29: Actelion deals by industry sector
  • Figure 30: Actelion deals by technology type
  • Figure 31: Actelion deals by stage of development
  • Figure 32: Actelion deals by therapy area
  • Figure 33: Alexion Pharmaceuticals dealmaking frequency 2010-2015
  • Figure 34: Alexion Pharmaceuticals deals by type
  • Figure 35: Alexion Pharmaceuticals deals by industry sector
  • Figure 36: Alexion Pharmaceuticals deals by technology type
  • Figure 37: Alexion Pharmaceuticals deals by stage of development
  • Figure 38: Alexion Pharmaceuticals deals by therapy area
  • Figure 39: Alkermes dealmaking frequency 2010-2015
  • Figure 40: Alkermes deals by type
  • Figure 41: Alkermes deals by industry sector
  • Figure 42: Alkermes deals by technology type
  • Figure 43: Alkermes deals by stage of development
  • Figure 44: Alkermes deals by therapy area
  • Figure 45: Allergan dealmaking frequency 2010-2015
  • Figure 46: Allergan deals by type
  • Figure 47: Allergan deals by industry sector
  • Figure 48: Allergan deals by technology type
  • Figure 49: Allergan deals by stage of development
  • Figure 50: Allergan deals by therapy area
  • Figure 51: Amgen dealmaking frequency 2010-2015
  • Figure 52: Amgen deals by type
  • Figure 53: Amgen deals by industry sector
  • Figure 54: Amgen deals by technology type
  • Figure 55: Amgen deals by stage of development
  • Figure 56: Amgen deals by therapy area
  • Figure 57: Bavarian Nordic dealmaking frequency 2010-2015
  • Figure 58: Bavarian Nordic deals by type
  • Figure 59: Bavarian Nordic deals by industry sector
  • Figure 60: Bavarian Nordic deals by technology type
  • Figure 61: Bavarian Nordic deals by stage of development
  • Figure 62: Bavarian Nordic deals by therapy area
  • Figure 63: Biocon dealmaking frequency 2010-2015
  • Figure 64: Biocon deals by type
  • Figure 65: Biocon deals by industry sector
  • Figure 66: Biocon deals by technology type
  • Figure 67: Biocon deals by stage of development
  • Figure 68: Biocon deals by therapy area
  • Figure 69: Biogen Idec dealmaking frequency 2010-2015
  • Figure 70: Biogen Idec deals by type
  • Figure 71: Biogen Idec deals by industry sector
  • Figure 72: Biogen Idec deals by technology type
  • Figure 73: Biogen Idec deals by stage of development
  • Figure 74: Biogen Idec deals by therapy area
  • Figure 75: BioMarin Pharmaceuticals dealmaking frequency 2010-2015
  • Figure 76: BioMarin Pharmaceuticals deals by type
  • Figure 77: BioMarin Pharmaceuticals deals by industry sector
  • Figure 78: BioMarin Pharmaceuticals deals by technology type
  • Figure 79: BioMarin Pharmaceuticals deals by stage of development
  • Figure 80: BioMarin Pharmaceuticals deals by therapy area
  • Figure 81: Celgene dealmaking frequency 2010-2015
  • Figure 82: Celgene deals by type
  • Figure 83: Celgene deals by industry sector
  • Figure 84: Celgene deals by technology type
  • Figure 85: Celgene deals by stage of development
  • Figure 86: Celgene deals by therapy area
  • Figure 87: CSL dealmaking frequency 2010-2015
  • Figure 88: CSL deals by type
  • Figure 89: CSL deals by industry sector
  • Figure 90: CSL deals by technology type
  • Figure 91: CSL deals by stage of development
  • Figure 92: CSL deals by therapy area
  • Figure 93: Cubist dealmaking frequency 2010-2015
  • Figure 94: Cubist partnering deals by type
  • Figure 95: Cubist deals by industry sector
  • Figure 96: Cubist deals by technology type
  • Figure 97: Cubist deals by stage of development
  • Figure 98: Cubist deals by therapy area
  • Figure 99: Dendreon dealmaking frequency 2010-2015
  • Figure 100: Dendreon deals by type
  • Figure 101: Dendreon deals by industry sector
  • Figure 102: Dendreon deals by technology type
  • Figure 103: Dendreon deals by stage of development
  • Figure 104: Dendreon deals by therapy area
  • Figure 105: Emergent BioSolutions dealmaking frequency 2010-2015
  • Figure 106: Emergent BioSolutions deals by type
  • Figure 107: Emergent BioSolutions deals by industry sector
  • Figure 108: Emergent BioSolutions deals by technology type
  • Figure 109: Emergent BioSolutions deals by stage of development
  • Figure 110: Emergent BioSolutions deals by therapy area
  • Figure 111: Endo dealmaking frequency 2010-2015
  • Figure 112: Endo deals by type
  • Figure 113: Endo deals by industry sector
  • Figure 114: Endo deals by technology type
  • Figure 115: Endo deals by stage of development
  • Figure 116: Endo deals by therapy area
  • Figure 117: Galapagos dealmaking frequency 2010-2015
  • Figure 118: Galapagos deals by type
  • Figure 119: Galapagos deals by industry sector
  • Figure 120: Galapagos deals by technology type
  • Figure 121: Galapagos deals by stage of development
  • Figure 122: Galapagos deals by therapy area
  • Figure 123: Genmab dealmaking frequency 2010-2015
  • Figure 124: Genmab deals by type
  • Figure 125: Genmab deals by industry sector
  • Figure 126: Genmab deals by technology type
  • Figure 127: Genmab deals by stage of development
  • Figure 128: Genmab deals by therapy area
  • Figure 129: Gilead Sciences dealmaking frequency 2010-2015
  • Figure 130: Gilead Sciences deals by type
  • Figure 131: Gilead Sciences deals by industry sector
  • Figure 132: Gilead Sciences deals by technology type
  • Figure 133: Gilead Sciences deals by stage of development
  • Figure 134: Gilead Sciences deals by therapy area
  • Figure 135: Grifols dealmaking frequency 2010-2015
  • Figure 136: Grifols deals by type
  • Figure 137: Grifols deals by industry sector
  • Figure 138: Grifols deals by technology type
  • Figure 139: Grifols deals by stage of development
  • Figure 140: Grifols deals by therapy area
  • Figure 141: Ipsen dealmaking frequency 2010-2015
  • Figure 142: Ipsen deals by type
  • Figure 143: Ipsen deals by industry sector
  • Figure 144: Ipsen deals by technology type
  • Figure 145: Ipsen deals by stage of development
  • Figure 146: Ipsen deals by therapy area
  • Figure 147: Isis Pharmaceuticals dealmaking frequency 2010-2015
  • Figure 148: Isis Pharmaceuticals deals by type
  • Figure 149: Isis Pharmaceuticals deals by industry sector
  • Figure 150: Isis Pharmaceuticals deals by technology type
  • Figure 151: Isis Pharmaceuticals deals by stage of development
  • Figure 152: Isis Pharmaceuticals deals by therapy area
  • Figure 153: Jazz Pharmaceuticals dealmaking frequency 2010-2015
  • Figure 154: Jazz Pharmaceuticals deals by type
  • Figure 155: Jazz Pharmaceuticals deals by industry sector
  • Figure 156: Jazz Pharmaceuticals deals by technology type
  • Figure 157: Jazz Pharmaceuticals deals by stage of development
  • Figure 158: Jazz Pharmaceuticals deals by therapy area
  • Figure 159: LFB dealmaking frequency 2010-2015
  • Figure 160: LFB deals by type
  • Figure 161: LFB deals by industry sector
  • Figure 162: LFB deals by technology type
  • Figure 163: LFB deals by stage of development
  • Figure 164: LFB deals by therapy area
  • Figure 165: Medivation dealmaking frequency 2010-2015
  • Figure 166: Medivation deals by type
  • Figure 167: Medivation deals by industry sector
  • Figure 168: Medivation deals by technology type
  • Figure 169: Medivation deals by stage of development
  • Figure 170: Medivation deals by therapy area
  • Figure 171: Merck KGaA dealmaking frequency 2010-2015
  • Figure 172: Merck KGaA deals by type
  • Figure 173: Merck KGaA deals by industry sector
  • Figure 174: Merck KGaA deals by technology type
  • Figure 175: Merck KGaA deals by stage of development
  • Figure 176: Merck KGaA deals by therapy area
  • Figure 177: Morphosys dealmaking frequency 2010-2015
  • Figure 178: Morphosys deals by type
  • Figure 179: Morphosys deals by industry sector
  • Figure 180: Morphosys deals by technology type
  • Figure 181: Morphosys deals by stage of development
  • Figure 182: Morphosys deals by therapy area
  • Figure 183: Nektar Therapeutics dealmaking frequency 2010-2015
  • Figure 184: Nektar Therapeutics deals by type
  • Figure 185: Nektar Therapeutics deals by industry sector
  • Figure 186: Nektar Therapeutics deals by technology type
  • Figure 187: Nektar Therapeutics deals by stage of development
  • Figure 188: Nektar Therapeutics deals by therapy area
  • Figure 189: Novo Nordisk dealmaking frequency 2010-2015
  • Figure 190: Novo Nordisk deals by type
  • Figure 191: Novo Nordisk deals by industry sector
  • Figure 192: Novo Nordisk deals by technology type
  • Figure 193: Novo Nordisk deals by stage of development
  • Figure 194: Novo Nordisk deals by therapy area
  • Figure 195: NPS Pharmaceuticals dealmaking frequency 2010-2015
  • Figure 196: NPS Pharmaceuticals deals by type
  • Figure 197: NPS Pharmaceuticals deals by industry sector
  • Figure 198: NPS Pharmaceuticals deals by technology type
  • Figure 199: NPS Pharmaceuticals deals by stage of development
  • Figure 200: NPS Pharmaceuticals deals by therapy area
  • Figure 201: PDL BioPharma dealmaking frequency 2010-2015
  • Figure 202: PDL BioPharma deals by type
  • Figure 203: PDL BioPharma deals by industry sector
  • Figure 204: PDL BioPharma deals by technology type
  • Figure 205: PDL BioPharma deals by stage of development
  • Figure 206: PDL BioPharma deals by therapy area
  • Figure 207: Pharmacyclics dealmaking frequency 2010-2015
  • Figure 208: Pharmacyclics deals by type
  • Figure 209: Pharmacyclics deals by industry sector
  • Figure 210: Pharmacyclics deals by technology type
  • Figure 211: Pharmacyclics deals by stage of development
  • Figure 212: Pharmacyclics deals by therapy area
  • Figure 213: Questcor Pharmaceuticals dealmaking frequency 2010-2015
  • Figure 214: Questcor Pharmaceuticals deals by type
  • Figure 215: Questcor Pharmaceuticals deals by industry sector
  • Figure 216: Questcor Pharmaceuticals deals by technology type
  • Figure 217: Questcor Pharmaceuticals deals by stage of development
  • Figure 218: Questcor Pharmaceuticals deals by therapy area
  • Figure 219: Regeneron Pharmaceuticals dealmaking frequency 2010-2015
  • Figure 220: Regeneron Pharmaceuticals deals by type
  • Figure 221: Regeneron Pharmaceuticals deals by industry sector
  • Figure 222: Regeneron Pharmaceuticals deals by technology type
  • Figure 223: Regeneron Pharmaceuticals deals by stage of development
  • Figure 224: Regeneron Pharmaceuticals deals by therapy area
  • Figure 225: Roche dealmaking frequency 2010-2015
  • Figure 226: Roche deals by type
  • Figure 227: Roche deals by industry sector
  • Figure 228: Roche deals by technology type
  • Figure 229: Roche deals by stage of development
  • Figure 230: Roche deals by therapy area
  • Figure 231: Salix Pharmaceuticals dealmaking frequency 2010-2015
  • Figure 232: Salix Pharmaceuticals deals by type
  • Figure 233: Salix Pharmaceuticals deals by industry sector
  • Figure 234: Salix Pharmaceuticals deals by technology type
  • Figure 235: Salix Pharmaceuticals deals by stage of development
  • Figure 236: Salix Pharmaceuticals deals by therapy area
  • Figure 237: SciClone Pharmaceuticals dealmaking frequency 2010-2015
  • Figure 238: SciClone Pharmaceuticals deals by type
  • Figure 239: SciClone Pharmaceuticals deals by industry sector
  • Figure 240: SciClone Pharmaceuticals deals by technology type
  • Figure 241: SciClone Pharmaceuticals deals by stage of development
  • Figure 242: SciClone Pharmaceuticals deals by therapy area
  • Figure 243: Seattle Genetics dealmaking frequency 2010-2015
  • Figure 244: Seattle Genetics deals by type
  • Figure 245: Seattle Genetics deals by industry sector
  • Figure 246: Seattle Genetics deals by technology type
  • Figure 247: Seattle Genetics deals by stage of development
  • Figure 248: Seattle Genetics deals by therapy area
  • Figure 249: Shire dealmaking frequency 2010-2015
  • Figure 250: Shire deals by type
  • Figure 251: Shire deals by industry sector
  • Figure 252: Shire deals by technology type
  • Figure 253: Shire deals by stage of development
  • Figure 254: Shire deals by therapy area
  • Figure 255: Spectrum Pharmaceuticals dealmaking frequency 2010-2015
  • Figure 256: Spectrum Pharmaceuticals deals by type
  • Figure 257: Spectrum Pharmaceuticals deals by industry sector
  • Figure 258: Spectrum Pharmaceuticals deals by technology type
  • Figure 259: Spectrum Pharmaceuticals deals by stage of development
  • Figure 260: Spectrum Pharmaceuticals deals by therapy area
  • Figure 261: Sun Pharmaceutical dealmaking frequency 2010-2015
  • Figure 262: Sun Pharmaceutical deals by type
  • Figure 263: Sun Pharmaceutical deals by industry sector
  • Figure 264: Sun Pharmaceutical deals by technology type
  • Figure 265: Sun Pharmaceutical deals by stage of development
  • Figure 266: Sun Pharmaceutical deals by therapy area
  • Figure 267: Swedish Orphan Biovitrum dealmaking frequency 2010-2015
  • Figure 268: Swedish Orphan Biovitrum deals by type
  • Figure 269: Swedish Orphan Biovitrum deals by industry sector
  • Figure 270: Swedish Orphan Biovitrum deals by technology type
  • Figure 271: Swedish Orphan Biovitrum deals by stage of development
  • Figure 272: Swedish Orphan Biovitrum deals by therapy area
  • Figure 273: Teva dealmaking frequency 2010-2015
  • Figure 274: Teva deals by type
  • Figure 275: Teva deals by industry sector
  • Figure 276: Teva deals by technology type
  • Figure 277: Teva deals by stage of development
  • Figure 278: Teva deals by therapy area
  • Figure 279: The Medicines Company dealmaking frequency 2010-2015
  • Figure 280: The Medicines Company deals by type
  • Figure 281: The Medicines Company deals by industry sector
  • Figure 282: The Medicines Company deals by technology type
  • Figure 283: The Medicines Company deals by stage of development
  • Figure 284: The Medicines Company deals by therapy area
  • Figure 285: UCB dealmaking frequency 2010-2015
  • Figure 286: UCB deals by type
  • Figure 287: UCB deals by industry sector
  • Figure 288: UCB deals by technology type
  • Figure 289: UCB deals by stage of development
  • Figure 290: UCB deals by therapy area
  • Figure 291: United Therapeutics dealmaking frequency 2010-2015
  • Figure 292: United Therapeutics deals by type
  • Figure 293: United Therapeutics deals by industry sector
  • Figure 294: United Therapeutics deals by technology type
  • Figure 295: United Therapeutics deals by stage of development
  • Figure 296: United Therapeutics deals by therapy area
  • Figure 297: Valeant: Dealmaking frequency 2010-2015
  • Figure 298: Valeant: Partnering deals by type
  • Figure 299: Valeant: Partnering deals by industry sector
  • Figure 300: Valeant: Partnering deals by technology type
  • Figure 301: Valeant: Partnering deals by stage of development
  • Figure 302: Valeant: Partnering deals by therapy area
  • Figure 303: Vertex Pharmaceuticals dealmaking frequency 2010-2015
  • Figure 304: Vertex Pharmaceuticals deals by type
  • Figure 305: Vertex Pharmaceuticals deals by industry sector
  • Figure 306: Vertex Pharmaceuticals deals by technology type
  • Figure 307: Vertex Pharmaceuticals deals by stage of development
  • Figure 308: Vertex Pharmaceuticals deals by therapy area
  • Figure 309: Online partnering resources
  • Figure 310: Deal type definitions
  • Figure 311: Licensing and collaboration agreement between Bayer Healthcare and Regeneron Pharmaceuticals, January 2014
Back to Top